Mineralys CMO sells shares, exercises options
Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom Rodman reported option exercises and stock sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom Rodman reported option exercises and stock sales. On July 13, 2026 he exercised options for 14,058 common shares at strike prices of $1.08, $10.20 and $14.25. He then sold a total of 20,407 shares in open-market transactions at weighted-average prices of $27.5798 and $26.6112, pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. After these transactions, he owns 51,384 common shares directly.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
8 txns
Insider
Rodman David Malcom
Role
Chief Medical Officer
Sold
20,407 shs ($557K)
Approx. gross sale proceeds
$557K
Approx. exercise cost
$102K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F3 | 6,349 | $26.6112 | $169K |
| Exercise | Stock Option F1, F4 | 3,542 | $0.00 | $0.00 |
| Exercise | Stock Option F1, F5 | 4,167 | $0.00 | $0.00 |
| Exercise | Stock Option F1, F5 | 6,349 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 3,542 | $10.20 | $36K |
| Exercise | Common Stock F1 | 4,167 | $14.25 | $59K |
| Exercise | Common Stock F1 | 6,349 | $1.08 | $7K |
| Sale | Common Stock F1, F2 | 14,058 | $27.5798 | $388K |
Holdings After Transaction:
Stock Option — 188,959 contracts (Direct);
Common Stock — 51,384 shares (Direct)
Footnotes (5)
- F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
- F2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.965 to $27.750. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- F3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.41 to $27.15. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- F4. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.
- F5. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
Key Figures
Shares sold: 20,407 shares
Shares acquired via option exercise: 14,058 shares
Post-transaction holdings: 51,384 shares
+3 more
6 metrics
Shares sold
20,407 shares
Total Mineralys common shares sold on July 13 and 15, 2026
Shares acquired via option exercise
14,058 shares
Common shares received from option exercises on July 13, 2026
Post-transaction holdings
51,384 shares
Common shares directly owned after the July 15, 2026 sale
Sale price July 13
$27.5798 per share
Weighted-average price for shares sold on July 13, 2026
Sale price July 15
$26.6112 per share
Weighted-average price for shares sold on July 15, 2026
Option strike prices
$1.08, $10.20, $14.25
Exercise prices for options converted into common stock on July 13, 2026
Key Terms
Rule 10b5-1 trading plan, weighted-average price, Stock Option, derivative security
4 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted-average price financial
"The price reported in Column 4 is a weighted-average price."
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
Stock Option financial
"The stock option vests in monthly installments over a period of four years"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Mineralys (MLYS) Chief Medical Officer David Rodman report?
David Rodman reported a combination of stock option exercises and open-market sales of Mineralys Therapeutics (MLYS) common stock. He exercised options for 14,058 shares and sold 20,407 shares in total, all under a pre-arranged Rule 10b5-1 trading plan.
What stock options did the Mineralys (MLYS) CMO exercise in this filing?
He exercised options into 14,058 Mineralys common shares. The associated strike prices were $1.08 for 6,349 shares, $14.25 for 4,167 shares, and $10.20 for 3,542 shares, converting previously granted stock options into common stock.
Were the Mineralys (MLYS) insider stock sales made under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on October 6, 2025. Such plans pre-schedule trades, indicating the timing of these sales was set in advance rather than decided opportunistically.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates